Sol-Gel Technologies Stock (NASDAQ: SLGL)

Sol-Gel Technologies

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

Wall-Street_1 copy

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

BAOS

CHEK

CREV

JTAI

RENB

SLGL

US Stocks Gain, Nasdaq Surges Over 100 Points

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Pre-Market Outlook

Movers

AMPG

AVGR

BIPC

FDSB

HSDT

KORE

LAES

LIND

NCRA

NEUE

NVNI

RELI

TIVC

TLRY

TOVX

Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket

Biotech

Earnings

Earnings Misses

Penny Stocks

Small Cap

Analyst Ratings

General

Cue Biopharma, Inc. (NASDAQ: CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.

Cue Biopharma, Inc. Reports Q2 Loss, Tops Revenue Estimates

Sol-Gel Technologies Ltd. - Ordinary Shares

Sol-Gel Technologies Ltd

Press Releases

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice

Health Care

Management

Sol-Gel Technologies Announces Management Realignment

Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement

Financing

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Sol-Gel Announces Reverse Share Split

Raymond James

HC Wainwright & Co.

Jefferies

Comments

Sol-Gel Technologies

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell